Nitrosamine Risk in Pharmaceutical Intermediates

Nitrosamine Risk Starts Upstream: Materials, Routes and Change Control

Nitrosamine control is most effective when it begins before the final API or drug product. This article examines how raw materials, intermediates, reagents, recovered solvents, route design and change control shape risk.

Nitrosamine control is most effective when it begins before the final API or drug product. Raw materials, intermediates, reagents, recovered solvents, route design, supplier knowledge and change control can all shape risk.

Nitrosamine risk is sometimes approached mainly as a finished-product testing question. Testing is important, but current regulatory guidance treats control as a lifecycle activity built on knowledge of materials, suppliers, process chemistry, manufacturing conditions and product stability.

Some N-nitrosamines are potent mutagenic carcinogens in animal studies. The U.S. Food and Drug Administration distinguishes between small-molecule nitrosamine impurities and nitrosamine drug substance-related impurities, or NDSRIs, which share structural similarity with an active pharmaceutical ingredient.

FDA’s revised September 2024 guidance recommends that manufacturers of active pharmaceutical ingredients and drug products assess potential causes, conduct confirmatory testing when warranted and establish appropriate controls. In the European Union, EMA describes ongoing responsibilities for marketing authorisation holders to evaluate, monitor and mitigate risk throughout a medicine’s lifecycle.

These frameworks differ in legal status and application. FDA guidance communicates the Agency’s recommendations, while applicable statutory, CGMP and filing requirements remain separate. The precise requirements for any product depend on its market, authorisation and current regulatory status.

Why assessment begins before the final API

Nitrosamine formation generally requires a chemically plausible combination of a nitrosating species and a suitable amine precursor under conditions that permit a reaction. The presence of an amine or nitrite alone does not demonstrate that a nitrosamine will form.

Risk can be influenced by:

The identity and concentration of potential precursors
The reaction sequence and point of addition
pH, temperature and reaction time
Quench and work-up conditions
Carryover between process steps
Purge through extraction, crystallisation or other operations
Storage conditions and possible degradation pathways

Because relevant precursors may enter several stages before the final API, an assessment limited to the last synthetic step can overlook meaningful sources.

Raw materials and intermediates can carry hidden risk

A starting material or intermediate may introduce an amine-containing structure, a nitrosating impurity or trace contamination originating from its own manufacturing process. Standard identity and assay data may not fully describe every impurity relevant to a nitrosamine assessment.

Useful upstream knowledge may include the material’s manufacturing route, reagent classes, solvent history, impurity profile and the supplier’s controls over cross-contamination. The necessary level of detail should be determined through a scientifically justified, risk-based assessment rather than a universal checklist.

Source changes deserve particular attention. Two suppliers can provide material meeting the same general specification while using different routes, reagents or recovery practices. Those differences may create different trace-impurity profiles even when the main material meets its established release tests.

Reagents, solvents and process conditions

Nitrite salts are recognised nitrosating sources, but a route assessment should consider other plausible nitrosating species and their potential origin. Amines may be intentionally used as reagents or bases, occur as impurities, or arise from degradation of certain materials.

The important question is not simply whether these substances appear anywhere in a process. It is whether a chemically credible combination can occur at relevant concentrations and under conditions that support formation.

Process mapping should therefore consider additions, order of operations, acidic conditions, temperature excursions, hold times and the fate of residues from previous steps. Quenches and work-ups should be included because they may bring components together under conditions different from the principal reaction.

Recovered solvents require traceability

Recovered solvents can support resource efficiency, but they require specific consideration in nitrosamine risk assessments. Recovery does not inherently create nitrosamines. The concern is that a recovered stream may carry or concentrate nitrosamines, nitrosating species or amine precursors from an earlier use.

Risk can be affected by whether recovery is internal or external, whether streams from different processes are combined, and whether the recovery operation has adequate segregation, traceability and impurity controls.

Relevant questions may include:

Which processes contributed to the recovered stream?
Could nitrosamines or their precursors survive or concentrate during recovery?
Are recovery cycles and reuse conditions defined?
Are source changes and cross-process mixing controlled?
Do acceptance criteria address the identified risk?

Replacing every recovered solvent with virgin material is not automatically required or scientifically necessary. The objective is to understand the stream and establish controls proportionate to a credible risk.

Route design should consider formation, fate and purge

A route-based assessment should identify both where a nitrosamine could form and what happens afterward. Formation early in a synthesis does not necessarily mean that the impurity will remain in the API; later operations may remove it. Conversely, formation near the end of a process may provide fewer opportunities for purge.

Purge should not be assumed solely from the number of subsequent steps. Its credibility depends on the impurity’s physical and chemical properties and on the actual process operations. Where risk is significant, process data, appropriately designed studies or suitable analytical evidence may be needed to support the conclusion.

Possible mitigation strategies can include changing a reagent, modifying reaction conditions, improving material controls, preventing cross-contamination or redesigning part of a route. Any change must also be evaluated for product quality, process performance and applicable regulatory reporting.

Change control is part of lifecycle management

A nitrosamine assessment should not be treated as a one-time document. Changes to suppliers, synthetic routes, reagent grades, solvent-recovery arrangements, equipment, manufacturing sites, batch scale, hold times or storage conditions can alter the original risk conclusion.

Effective change control asks a forward-looking question: could this change introduce a new nitrosating source, amine precursor, contamination pathway or formation condition?

The assessment should occur before implementation whenever practicable and involve the appropriate quality, chemistry, analytical and regulatory functions. For authorised medicines, manufacturing changes may require regulatory submissions or notifications according to the applicable jurisdiction and type of change.

Testing supports—but does not replace—prevention

Confirmatory testing can determine whether a predicted risk is present, but testing alone cannot provide complete process understanding. Nitrosamines may require highly sensitive, compound-specific analytical methods, and matrix interference or analytical artefacts can complicate measurement.

Methods should be suitable for the relevant nitrosamine, material and required sensitivity. Sampling plans should also reflect process knowledge rather than relying only on a single convenient batch or manufacturing stage.

Acceptable intake values and recommended analytical approaches continue to evolve. FDA and EMA maintain live resources that should be consulted for the latest compound-specific information instead of relying on an archived table or secondary summary.

What this means for intermediate sourcing

For suppliers of pharmaceutical intermediates and custom synthesis services, upstream nitrosamine risk management places greater value on route transparency, material traceability and timely change communication.

At the enquiry stage, project teams can define the synthetic-route information, source history, process-change communication and analytical documentation required for the material’s intended use. Rlavie can discuss project-specific expectations for Custom Synthesis work; customers remain responsible for determining the controls and evidence required under their applicable quality and regulatory framework.

Early discussion is usually more effective than attempting to reconstruct the complete route history after a risk has been identified.

Conclusion

Nitrosamine risk management begins with chemistry and process knowledge, not only with a final analytical result. Raw materials, intermediates, reagents, recovered solvents, manufacturing routes and later changes can each influence whether a credible formation or contamination pathway exists.

A robust approach connects upstream supplier knowledge with route assessment, suitable controls, change management and risk-based testing. It also remains responsive to evolving scientific and regulatory information.

This article is for general industry information and does not constitute regulatory, quality or legal advice. Companies should consult the current requirements and guidance applicable to their products and markets.